Actinic keratoses

Australian Family Physician

Volumn 36, Issue 7, 2007, Pages 539-541

  Chia, Alvin ^a   Moreno, Gilberto ^b   Lim, Adrian ^a   Shumack, Stephen ^a,b  

^a St George Dermatol/Skin Cancer C   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETABOLITE; DICLOFENAC; FLUOROURACIL; NONSTEROID ANTIINFLAMMATORY AGENT;

AUSTRALIA; CRYOTHERAPY; HUMAN; PHOTOSENSITIVITY DISORDER; REVIEW; SKIN TUMOR; SUNLIGHT;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIMETABOLITES; AUSTRALIA; CRYOTHERAPY; DICLOFENAC; FLUOROURACIL; HUMANS; PHOTOSENSITIVITY DISORDERS; SKIN NEOPLASMS; SUNLIGHT;

EID: 34547777409     PISSN: 03008495     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Kennedy C, Bajdik C, Willemze R, et al. The influence of painful sunburns and lifetime sun exposure on the risk of actinic keratoses, seborrheic warts, melanocytic nevi, atypical nevi, and skin cancer. J Inv Dermatol 2003;120:1087-93.
2. Marks R. Epidemiology of non-melanoma skin cancer and solar keratoses in Australia: a tale of self immolation in Elysian fields. Australas J Dermatol 1997;38(Suppl 1):S26-9.
3. Frost CA, Green AC. Epidemiology of solar keratoses. Br J Dermatol 1994;151:455-64.
4. Green A, Beardmore G, Hart V, et al. Skin cancer in a Queensland population. J Am Acad Dermatol 1988;19:129-38.
5. Mortier L, Marchetti P, Delaporte E, et al. Progression of actinic keratosis to squamous cell carcinoma of the skin correlates with deletion of the 9p21 region encoding the p16(INK4a) tumour suppressor. Cancer Lett 2002;176:205-14.
6. Simon JC, Tigelaar RE, Bergstresser PR, et al. UVB radiation converts LC from immunogenic to tolerogenic antigen presenting cells: induction of specific clonal anergy in CD4+ T helper 1 cells. J Immunol 1991;146:485-91.
7. Yoshikawa T, Rae V, Bruins-Slot W, et al. Susceptibility to effect of UVB radiation on induction of contact hypersensitivity as a risk factor for skin cancer in humans. J Invest Dermatol 1990;95:530-6.
8. Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratosis to squamous cell carcinoma. Lancet 1998;1:795-7.
9. Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol 2000;42(1 Pt 2):23-4.
10. Marks R, Foley P, Goodman G, et al. Spontaneous remission of solar keratosis: the case for conservative management. Br J Dermatol 1986;115:649-55.
11. Green A, Battistutta D. Incidence and determinants of skin cancer in a high Australian population. Int J Cance 1990;15:356-61.
12. Lober B, Lober C, Accola J. Actinic keratosis is squamous cell carcinoma. J Am Acad Dermatol 2000;43:881-2.
13. Heaphy MR Jr, Ackerman AB. The nature of solar keratosis: a critical review in historical perspective. J Am Acad Dermatol 2000;43:138-50.
14. Marks R. Who benefits from calling a solar keratosis a squamous cell carcinoma? Br J Dermatol 2006;155:23-6.
15. Thompson SC, Jolley D, Marks R. Reduction of solar keratoses by regular sunscreen use. N Engl J Med 1993;329:1147-51.
16. Thai KE, Fergin P, Freeman M, et al. A prospective study of the use of cryosurgery for the treatment of actinic keratoses. Int J Dermatol 2004;43:687-92.
17. Tran H, Chen K, Shumack S. Summary of actinic keratosis studies with imiquimod 5% cream. Br J Dermatol 2003;149:37-9.
18. Dillaha CJ, Jansen GT, Honeycutt WM, et al. Further studies with topical 5-fluorouracil. Arch Dermatol 1965;92:410-7.
19. Eaglstein WH, Weinstein GD, Frost P. Fluorouracil: mechanism of action in human skin and actinic keratoses I: Effect on DNA synthesis in vivo. Arch Dermatol 1970;101:132-9.
20. Labandeira J, Pereiro M Jr, Valdes F et al. Intermittent topical 5-fluorouracil is effective without significant irritation in the treatment of actinic keratoses but prolongs treatment duration. Dermatol Surg 2004;30:517-20.
21. Higashi Y, Kanekura T, Kanzaki T. Enhanced expression of cyclooxygenase (COX)-2 in human skin epidermal cancer cells: Evidence for growth suppression by inhibiting COX-2 expression. Int J Cancer 2000;86:667-1.
22. Nelson C, Rigel D, Smoth S, et al. Phase IV, open label assessment of the treatment of actinic keratosis with 3% diclofenac sodium topical gel (Solaraze). J Drugs Dermatol 2004;3:401-7.
23. Gebauer K, Brown P, Varigos G. Topical diclofenac in hyaluron gel for the treatment of solar keratoses. Australas J Dermatol 2003;44:40-3.
24. Fritsch C, Homey B, Stahl W, et al. Preferential relative porphyrin enrichment in solar keratoses upon topical application of delta-aminolevulinic acid methylester. Photochem Photobiol 1998;68:218-21.
25. Pariser D, Lowe N, Stewart D, et al. Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomised multicenter trial. J Am Acad Dermatol 2003;48:227-32.
26. Meyer T, Nindl I, Schmook T, et al. Induction of apoptosis by toll-like receptor-7 agonist in tissue cultures. Br J Dermatol 2003;149(Supp 66):9-13.
27. Lebwohl M, Dinehart S, Whiting D, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomised, double blind, parallel group, vehicle controlled trials. J Am Acad Dermatol 2004;50:714-21.
28. Korman N, Moy R, Ling M, et al. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomised, double blind, parallel group, vehicle controlled trials. Arch Dermatol 2005;141:467-73.
29. Szeimies R-M, Gerritsen M-J, Gupta G, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomised, double blind, vehicle controlled, clinical trial with histology. J Am Acad Dermatol 2004;51:547-55.
30. Salasche S, Levine N, Morrison L. Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: an open label trial. J Am Acad Dematol 2002;47:571-7.
31. Chen K, Yap L, Marks R, et al. Short course therapy with imiquimod 5% cream for solar keratoses: a randomised controlled trial. Australas J Dermatol 2003;44:250-5.
32. Euvrard S, Kanitakis J, Pouteil-Noble C, et al. Comparative epidemiologic study on premalignant and malignant epithelial cutaneous lesions developing after kidney and heart transplantation. J Am Acad Dermatol 1995;33:222-9.
33. Ulrich C, Busch JO, Meyer T, et al. Successful treatment of multiple actinic keratoses in organ transplant patients with topical 5% imiquimod: a report of six cases. Br J Dermatol 2006;155:451-4.
34. Ogbourne S, Suhrbier A, Jones B, et al. Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death. Cancer Res 2004;64:2833-9.